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Review Article
A well-designed trial derives its credibility from the inclusion of a prespecified, a priori hypothesis that helps its authors avoid making potentially false positive claims on the basis of an exploratory analysis of 
the data. Nevertheless, an unreasonable yet widespread practice is the labeling 
of all randomized trials as either positive or negative on the basis of whether the 
P value for the primary outcome is less than 0.05. This view is overly simplistic. 
P values should be interpreted as a continuum wherein the smaller the P value, the 
greater the strength of the evidence for a real treatment effect.1-3 Confidence inter-
vals are also useful in indicating the range of uncertainty around the estimated 
treatment effect. Moreover, the interpretation of any trial should depend on the 
totality of the evidence (i.e., the primary, secondary, and safety outcomes), not just 
a single end point.
Herein we outline the thought processes to follow when the primary outcome 
of a trial is first perceived as negative. In a subsequent issue of the Journal, we will 
review the questions to ask when the outcomes of a trial appear to be positive. We 
illustrate our points with examples from trials — primarily from cardiovascular 
studies, which constitute our sphere of expertise — but the underlying issues apply 
to the whole of medicine.
K e y Ques tions W hen the Pr im a r y Ou t come Fa il s
The failure to achieve the 5% level of significance is certainly not promising for 
the test treatment. Typical first reactions include the following: What went wrong? 
Is the treatment truly ineffective? Are there glimmers of hope? What next? Ad-
dressing the 12 questions below provides a path forward (Table 1).
Is There Some Indication of Potential Benefit?
Whether a signal of treatment benefit (a “trend”) should be inferred from a P value 
greater than 0.05 requires thoughtful consideration. When the primary findings 
of a trial are completely neutral, interpretation is straightforward. For instance, 
when the PERFORM trial of terutroban versus aspirin in patients with ischemic 
stroke (see box for a list of the complete names of all trials mentioned in this 
article)4 showed no significant between-group difference with respect to the com-
posite primary outcome — ischemic stroke, myocardial infarction, or other vascular 
cause of death (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.12) — 
the trial was stopped early because of futility, and no safety advantages were de-
tected for terutroban. These findings support the interpretation of a “negative trial.”
In contrast, in the TORCH trial,5 in which the effects of salmeterol plus flutica-
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sone propionate versus placebo were assessed in 
patients with chronic obstructive pulmonary dis-
ease (COPD), the P value for the primary out-
come of death from any cause was 0.052, and 
“significant benefits in all other outcomes” (e.g., 
COPD exacerbations and health status) were found. 
Consequently, the findings of this trial merited 
a more constructive interpretation than that of 
“negative trial.”
Was the Trial Underpowered?
The inclusion of too few patients in a study in-
creases the risk that a significant treatment bene-
fit will not be shown, even if such an effect 
exists (a type 2 error). For instance, in a trial of 
bisoprolol versus placebo in patients with sys-
tolic heart failure,6 the hazard ratio for the pri-
mary outcome, death from any cause, was 0.80 
(95% CI, 0.56 to 1.15; P = 0.22). However, with 
only 621 patients, the trial was underpowered. 
Fortunately, the sponsors persisted, and the sub-
sequent CIBIS II trial,7 which included 2647 pa-
tients, showed that mortality was lower among 
those who received bisoprolol than among those 
who received placebo (hazard ratio, 0.66; 95% CI, 
0.54 to 0.81; P<0.0001). Note that the estimated 
34% lower mortality with bisoprolol in this 
larger trial was within the 95% confidence inter-
val reported in the first study.
In general, when a trial is too small to detect 
modest treatment effects, it is appropriate to 
describe the findings as inconclusive rather than 
negative. An adequately powered study requires 
the accrual of a sufficient number of primary-
outcome events, which can be achieved by recruit-
ing more patients, enrolling patients at higher 
risk, prolonging follow-up, specifying an outcome 
that occurs more frequently (including the use of 
composite outcomes), or a combination thereof.
Was the Primary Outcome Appropriate  
(or Accurately Defined)?
The use of a composite outcome increases the 
number of primary events but does not necessar-
ily increase statistical power. For instance, in the 
PROactive trial,8 in which pioglitazone was com-
pared with placebo in patients with type 2 dia-
betes, the composite primary outcome was death, 
myocardial infarction, stroke, acute coronary syn-
drome, endovascular surgery, or leg amputation. 
With 514 primary events in the pioglitazone 
Is there some indication of potential benefit?
Was the trial underpowered?
Was the primary outcome appropriate (or accurately defined)?
Was the population appropriate?
Was the treatment regimen appropriate?
Were there deficiencies in trial conduct?
Is a claim of noninferiority of value?
Do subgroup findings elicit positive signals?
Do secondary outcomes reveal positive findings?
Can alternative analyses help?
Does more positive external evidence exist?
Is there a strong biologic rationale that favors the treatment?
Table 1. Questions to Ask When the Primary Outcome Fails.
ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial
ASPEN: Atorvastatin Study for Prevention of Coronary Heart Disease 
Endpoints in Non–Insulin-Dependent Diabetes Mellitus
BARI 2D: Bypass Angioplasty Revascularization Investigation 2 Diabetes
BEAUTIFUL: Ivabradine for Patients with Stable Coronary Artery Disease and 
Left-Ventricular Systolic Dysfunction
CAPRICORN: Carvedilol Postinfarction Survival Control in Left Ventricular 
Dysfunction
CARDS: Collaborative Atorvastatin Diabetes Study
CHAMPION trials: Cangrelor versus Standard Therapy to Achieve Optimal 
Management of Platelet Inhibition
CHARM-Preserved: Candesartan in Heart Failure Assessment of Reduction in 
Mortality and Morbidity
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
EXCEL: Evaluation of XIENCE PRIME Everolimus Eluting Stent System 
[EECSS] or XIENCE V EECSS versus Coronary Artery Bypass Surgery for 
Effectiveness of Left Main Revascularization
MATRIX: Minimizing Adverse Hemorrhagic Events by Transradial Access Site 
and Systemic Implementation of Angiox
MOXCON: Sustained Release Moxonidine for Congestive Heart Failure
PEGASUS-TIMI 54: Prevention of Cardiovascular Events in Patients with Prior 
Heart Attack Using Ticagrelor Compared to Placebo on a Background of 
Aspirin–Thrombolysis in Myocardial Infarction 54
PERFORM: Terutroban versus Aspirin in Patients with Cerebral Ischemic 
Events
PROactive: Prospective Pioglitazone Clinical Trial in Macrovascular Events
SHIFT: Systolic Heart Failure Treatment with the I
f
 Inhibitor Ivabradine Trial
SIGNIFY: Study Assessing the Morbidity–Mortality Benefits of the I
f
 Inhibitor 
Ivabradine in Patients with Coronary Artery Disease
SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels
STICH: Comparison of Surgical and Medical Treatment for Congestive Heart 
Failure and Coronary Artery Disease
SYMPLICITY HTN-3: Renal Denervation in Patients with Uncontrolled 
Hypertension
SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery
TARGET: Do Tirofiban and ReoPro Give Similar Efficacy Trial
TOPCAT: Treatment of Preserved Cardiac Function Heart Failure  
with an Aldosterone Antagonist
TORCH: Towards a Revolution in COPD Health
VALIANT: Valsartan in Acute Myocardial Infarction
Trial Names.
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group versus 572 primary events in the placebo 
group, the P value was 0.08. For the more con-
ventional composite outcome of death, myocar-
dial infarction, or stroke, there were 301 events 
in the pioglitazone group versus 358 events in 
the placebo group (P = 0.03). Thus, the addition 
of the extra components merely contributed ran-
dom noise, thereby diluting a potentially real 
effect into nonsignificance.
Trial success may hinge on definitions of 
the outcomes and on the methods used for 
their adjudication. For example, the CHAMPION 
PLATFORM trial of cangrelor versus clopidogrel 
in patients undergoing percutaneous coronary 
intervention (PCI)9 was stopped early for futility, 
since cangrelor was not shown to be beneficial 
with respect to the primary outcome (death, 
myocardial infarction, or ischemia-driven revas-
cularization within 48 hours). However, the defi-
nition of periprocedural myocardial infarction did 
not effectively identify infarctions that occurred 
soon after PCI among patients with biomarker-
positive acute coronary syndrome; a more pre-
cise definition of myocardial infarction might 
have contributed to a positive result.10 Thus, in a 
subsequent trial, CHAMPION PHOENIX,11 the rise 
and fall of biomarkers and clinical events were 
more carefully adjudicated to better discriminate 
periprocedural myocardial infarctions. A 22% low-
er rate of the 48-hour primary outcome (death, 
myocardial infarction, stent thrombosis, or 
ischemia-driven revascularization) with cangre-
lor than with clopidogrel was found (P = 0.005) 
and resulted in U.S. and European regulatory 
approval.
Was the Population Appropriate?
An apt question to ask when a new treatment 
fails is whether the wrong patient population 
was studied. For instance, two large trials of 
ivabradine involving patients with stable coro-
nary disease — BEAUTIFUL12 and SIGNIFY13 — 
failed to show any treatment benefit. However, 
in the SHIFT trial, which involved patients with 
chronic heart failure,14 the incidence of the pri-
mary outcome, cardiovascular death or hospital-
ization for heart failure, was 26% lower with 
ivabradine than with placebo (P<0.0001). Selec-
tion of the appropriate population on the basis 
of mechanistic effects and preliminary studies is 
essential for pivotal trial success.
Was the Treatment Regimen Appropriate?
Determination of the dosage regimen for a new 
drug in a pivotal trial can be challenging. In 
hindsight, the failures of tirofiban for the preven-
tion of ischemic events associated with percuta-
neous coronary revascularization in the TARGET 
trial15 and of moxonidine in the MOXCON trial16 
may well have been the result of dose selection 
— too low in the case of tirofiban and too high 
in the case of moxonidine. However, such mus-
ings, even if they are based on reexamination of 
the in vitro or phase 2 dose-ranging data, rarely 
lead to a subsequent trial in which the potential-
ly more appropriate dose is tested. Some pivotal 
trials minimize this risk by having a three-group 
design that includes two dosage regimens for 
the new drug; one example is PEGASUS-TIMI 54,17 
a study in which the lower, 60-mg dose of ticagre-
lor bested both a 90-mg dose and placebo for 
long-term use beyond 1 year after a myocardial 
infarction.
Were There Deficiencies in Trial Conduct?
A true treatment effect may be diluted, or disap-
pear entirely, if there is poor adherence to the 
study protocol. For instance, in the TOPCAT 
trial,18 a six-country study of spironolactone ver-
sus placebo that involved patients who had heart 
failure with preserved left ventricular ejection 
fraction, the composite outcome (cardiovascular 
death, cardiac arrest, or hospitalization for heart 
failure) showed only a nonsignificant trend in 
favor of spironolactone (hazard ratio 0.89; 95% 
CI, 0.77 to 1.04; P = 0.14). But patients in Russia 
and Georgia had very few primary outcome 
events,19 which suggests that there was some 
failure in study conduct in those countries or the 
enrollment of atypical patients. Confining analy-
sis to only the other four countries yielded a 
significant treatment benefit (hazard ratio, 0.82; 
95% CI, 0.69 to 0.98; P = 0.026). There has been 
debate as to whether this post hoc evidence is 
convincing enough to recommend spironolactone 
for patients who have heart failure with preserved 
left ventricular ejection fraction.
Is a Claim of Noninferiority of Value?
When a new treatment fails to show superiority 
to an active control, can noninferiority be claimed? 
Such a claim can be desirable if the new treat-
ment has other advantages (e.g., it is less invasive 
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or has fewer side effects), but in most cases it is 
appropriate to make that claim only if the non-
inferiority hypothesis was prespecified. For in-
stance, in the VALIANT trial,20 in which patients 
with complicated myocardial infarction received 
valsartan, captopril, or both, no benefit was 
shown for valsartan with regard to the primary 
outcome — death from any cause (hazard ratio, 
1.00; 97.5% CI, 0.90 to 1.11; P = 0.98). However, 
this confidence interval excluded the prespecified 
noninferiority margin of 1.13, which allowed 
investigators to conclude that valsartan was 
noninferior to captopril. Valsartan is thus an ac-
ceptable alternative for patients who cannot take 
captopril because of unacceptable side effects 
(e.g., cough, a taste disturbance, or rash).
Do Subgroup Findings Elicit Positive Signals?
Although it is appropriate to consider subgroup 
findings in any major trial, for a trial in which 
the overall result for the primary outcome is 
neutral or negative, such considerations are often 
misleading, since the potential for harm is often 
implied for the partner subgroups. Such qualita-
tive interactions are rarely plausible (unless a 
strong mechanistic underpinning is present), and 
the analyses are typically not adjusted for mul-
tiple comparisons; even if the findings from 
statistical tests of interaction are significant, 
such findings should usually be perceived as 
useful for generating hypotheses at best.21,22 In-
deed, we find it hard to think of an example in 
which an apparent benefit in a subgroup in a 
trial with a negative outcome has led to a con-
firmation in a subsequent trial.”
Nevertheless, such a scenario has motivated 
a large-scale, international trial of coronary 
revascularization strategies. The SYNTAX trial23 
of PCI versus coronary-artery bypass grafting 
(CABG) in patients with three-vessel or left main 
coronary artery disease yielded overall superior 
results with CABG. But for the subgroup with 
left main coronary artery disease (further exclud-
ing patients with high anatomical complexity), 
PCI appeared to be an acceptable (possibly 
 superior) alternative to CABG. This post hoc 
subgroup analysis served as the motivation for 
the ongoing EXCEL trial24 of PCI versus CABG 
in patients with left main coronary artery dis-
ease and low-to-moderate anatomical complex-
ity, the results of which are expected in the fall 
of 2016.
Do Secondary Outcomes Reveal Positive 
Findings?
If the primary outcome is negative, positive find-
ings for secondary outcomes are usually consid-
ered to be hypothesis-generating. Certainly, regu-
latory approval of a new drug is unlikely to 
follow. However, in some instances, secondary 
findings are compelling enough to affect guide-
lines and practice. For instance, in the ASCOT 
trial of amlodipine versus atenolol for hyperten-
sion,25 the hazard ratio for the composite pri-
mary outcome of nonfatal myocardial infarction 
or fatal coronary heart disease was 0.90 (95% CI, 
0.79 to 1.02; P = 0.11). However, the data support-
ing evidence of the superiority of amlodipine 
with respect to stroke, total cardiovascular events, 
death from any cause, and new-onset diabetes 
were overwhelming (P < 0.001, P<0.0001, P = 0.02, 
and P<0.0001, respectively) (Fig. 1). In hindsight, 
the primary outcome was an odd choice: the 
decision not to include stroke in a hypertension 
trial is unconventional. These results support 
recommendations against the use of atenolol as 
a first-line or second-line antihypertensive agent.
Few studies are appropriately powered to as-
sess effects on mortality. Proper interpretation 
can thus be challenging when a large trial shows 
a reduction in all-cause mortality, which is plau-
sible but not prespecified — especially if the 
primary outcome was negative. For example, in 
the MATRIX trial,26 patients with an acute coro-
nary syndrome who underwent PCI were random-
ly assigned to receive procedural anticoagulation 
with bivalirudin or unfractionated heparin. There 
was no significant difference in the 30-day com-
posite primary outcome of death, myocardial 
infarction, or stroke (relative risk, 0.94; 95% CI, 
0.81 to 1.09; P = 0.44). However, bivalirudin was 
associated with a markedly lower incidence of 
major bleeding as well as lower all-cause mortal-
ity (relative risk 0.71; 95% CI, 0.51 to 0.99; 
P = 0.04), a result also observed in some previous 
studies.27 This finding of reduced mortality with 
bivalirudin, although mechanistically plausible, 
ideally requires an additional adequately pow-
ered trial for resolution.
Can Alternative Analyses Help?
Covariate Adjustment
Covariate-adjusted analysis that includes baseline 
variables strongly related to the primary outcome 
will result in slightly greater statistical power 
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than a crude unadjusted analysis.22 However, if 
the covariates were not precisely prespecified 
or the adjusted analysis was not predeclared as 
primary, the finding will be perceived as interest-
ing and exploratory rather than one that affects 
the main conclusions of the trial.
For example, in the SPARCL trial of atorvas-
tatin versus placebo after stroke or transient 
ischemic attack,28 an unadjusted analysis yielded 
a borderline result in favor of atorvastatin for the 
primary outcome of recurrent stroke (P = 0.05). 
A prespecified, covariate-adjusted analysis that 
accounted for geographic region, entry event and 
duration, age, and sex yielded a hazard ratio of 
0.84 (95% CI, 0.71 to 0.99; P = 0.03). It is not 
clear which was the prespecified primary analy-
sis. Under the dubious premise that a signifi-
cance level of 5% should be of paramount im-
portance, one might debate whether the trial is 
“positive.” A more reasonable verdict is that 
overall there is modest evidence of a treatment 
benefit.
As-Treated or Per-Protocol Analyses
Analysis conducted according to the intention-
to-treat principle29 is the main method used to 
make a valid comparison between two treatment 
strategies according to the treatments that were 
actually delivered to all patients who underwent 
randomization. When an intention-to-treat analy-
sis fails to reach statistical significance, argu-
ments are advanced that nonadherence and 
treatment crossovers may have masked real treat-
ment effects and that as-treated or per-protocol 
analyses may get closer to the truth. Unfortu-
nately, the use of as-treated or per-protocol popu-
lations introduces selection bias, because patients 
who do not adhere to the treatment regimen and 
those who cross over to the other treatment 
strategy may have a different prognosis that is un-
related to actual treatment. Hence, such analyses 
rarely influence conclusions regarding treatment 
efficacy that are based on the intention-to-treat 
principle. However, on-treatment analyses may 
be considered appropriate when safety issues are 
examined.
In the STICH trial30 of CABG versus medical 
therapy in patients with left ventricular dysfunc-
tion (Fig. 2), in the intention-to-treat analysis, 
the hazard ratio for the primary outcome of 
death from any cause at a median follow-up of 
4 years was 0.86 (95% CI, 0.72 to 1.04; P = 0.12). 
Both an as-treated analysis (in which all patients 
who received CABG in the first year, including 
patients who crossed over to CABG, were com-
pared with those who received medical therapy 
alone) and a per-protocol analysis (in which data 
from any patients who crossed over within the 
first year were excluded) revealed lower mortality 
with CABG (P<0.001 and P = 0.005, respectively). 
Nonetheless, the principal conclusion remained 
“no significant difference between medical ther-
apy and CABG with respect to the primary out-
come.” In the intention-to-treat population, other 
Figure 1. Major Results from ASCOT.
Although the primary outcome did not reach statistical significance, numerous secondary outcomes were positive. 
Given the biologic plausibility of these findings and their consistency with the results from previous trials, the results 
of this study provide meaningful data that can be used to inform decisions regarding treatments for hypertension. 
Adapted from Dahlöf et al.25 CHD denotes coronary heart disease.
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benefits related to the outcomes of death from 
cardiovascular causes and the composite of death 
or hospitalization for cardiovascular disease were 
noted. Moreover, 10-year follow-up data in the 
STICH study has shown lower mortality with 
CABG than with medical therapy alone in the 
intention-to-treat population (hazard ratio, 0.84; 
95% CI, 0.73 to 0.97; P = 0.02).31 Thus, the total-
ity of the evidence supports an important role 
for CABG in patients with left ventricular dys-
function.
A related issue is the question of how to inter-
pret trials that have high rates of crossover. For 
example, in the BARI 2D trial32 of prompt coronary 
Figure 2. Results from the Primary Intention-to-Treat Population and the Alternative As-Treated and Per-Protocol Populations in the STICH Trial 
and the Potential Effect of Extended Follow-up.
Among 1212 patients with coronary artery disease and left ventricular ejection fraction of less than 35%, a total of 610 patients were randomly 
assigned to coronary-artery bypass grafting (CABG) and 602 patients to medical therapy. There was a nonsignificant difference in all-cause 
mortality in the prespecified, intention-to-treat analysis (Panel A). However, CABG was superior to medical therapy in an as-treated 
analysis in which the 592 patients who were treated with medical therapy throughout the first year after randomization were compared 
with the 620 patients who underwent CABG during initial assignment or as a result of crossover (Panel B). Similarly, CABG was superior 
to medical therapy in a per-protocol analysis in which the 537 patients who were randomly assigned to medical therapy who did not cross 
over to CABG during the first year of follow-up were compared with the 555 patients who were randomly assigned to and underwent CABG 
(Panel C). During an extended 10-year follow-up period, a significant mortality benefit with CABG emerged from an intention-to-treat 
analysis (Panel D). Adapted from Velazquez et al.30,31
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revascularization versus intensive medical therapy 
among patients with type 2 diabetes, there were 
no significant differences in the 5-year coprimary 
outcomes of death and major cardiovascular 
events (P = 0.97 and P = 0.70, respectively). How-
ever, 42% of patients in the medical-therapy 
group had undergone clinically indicated revas-
cularization, which raises questions about the 
value of medical therapy alone. Although such 
crossovers are an integral component of the 
initial conservative approach to treatment (and 
allowed revascularization to be avoided in the 
majority of patients), when crossovers occur fre-
quently, it is fair to ask whether an adequate 
distinction may be drawn between the alterna-
tive strategies.
Analyses of Repeat Events
In studies of chronic diseases such as heart fail-
ure, conventional composite outcome analyses 
concentrate on the time to the first event and 
ignore any repeat events that occur subsequently. 
This approach can lead to serious loss of statisti-
cal power and underestimation of a treatment 
effect.
For instance, in the CHARM-Preserved trial33 
of candesartan versus placebo in patients with 
heart failure and preserved left ventricular ejec-
tion fraction, the hazard ratio for the composite 
primary end point of time to first unplanned 
admission to the hospital for the management 
of worsening heart failure or cardiovascular death 
was 0.89 (95% CI, 0.77 to 1.03; P = 0.12). A sub-
sequent analysis of all heart-failure–associated 
hospitalizations, including repeat hospitalizations, 
showed a rate ratio of 0.75 (95% CI, 0.62 to 0.91; 
P = 0.003) (Fig. 3). The authors concluded that 
“recurrent events should be routinely incorpo-
rated into the analysis of future clinical trials in 
heart failure.”
Does More Positive External Evidence Exist?
When a negative primary outcome in an ade-
quately powered trial seems surprising given 
preexisting evidence, the strength and quality of 
prior studies must be scrutinized. First, nonran-
domized comparisons and surrogate end points 
from prior trials are not strong evidence. Evi-
dence from analogous trials or meta-analyses 
involving similar types of patients, treatments, 
and outcomes are more valuable.
For instance, in the ASPEN trial,34 in which the 
use of atorvastatin versus placebo was assessed 
in patients with type 2 diabetes, the hazard ratio 
for the composite primary outcome, a mix of 
cardiovascular events, was 0.90 (95% CI, 0.73 to 
1.12; P = 0.34). Given the positive outcomes as-
sociated with statins in other trials conducted in 
various patient populations, the results of the 
ASPEN trial were disappointing. In the larger 
Figure 3. Positive Findings Achieved by Means of an Alternative Analysis  
in the CHARM-Preserved Trial.
Among 3023 patients with heart failure and preserved left ventricular ejec-
tion fraction who underwent randomization, no significant difference was 
observed between the candesartan group and the placebo group with re-
spect to the primary outcome of cardiovascular death or hospitalization for 
heart failure in the prespecified time-to-first-event analysis (Panel A). How-
ever, when all events were accounted for in an alternative analysis, the data 
provided strong evidence for the effectiveness of candesartan (Panel B). 
Adapted from Rogers et al.33
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CARDS trial,35 which also involved the compari-
son of atorvastatin and placebo in patients with 
type 2 diabetes, the hazard ratio for the compos-
ite primary outcome (which was similar to that 
in the ASPEN trial) was 0.63 (95% CI, 0.48 to 
0.83; P = 0.001), and a meta-analysis of the two 
trials also produced a positive conclusion. The 
apparent inconsistency is not great (note the over-
lapping confidence intervals), so perhaps ASPEN 
was just the “unlucky” statin trial in which there 
was random variation away from a true treat-
ment effect.
Nonetheless, favorable findings from meta-
analyses should be interpreted cautiously, given 
the variations across trials in patient selection, 
the actual treatments studied, and definitions of 
outcomes and other differences in trial design 
and conduct. In general, evidence from one large, 
adequately powered randomized trial is preferred 
to that from a meta-analysis of smaller studies. 
Discrepancies between a large trial and a prior 
meta-analysis warrant further studies to resolve 
these inconsistencies.
Is There a Strong Biologic Rationale  
That Favors the Treatment?
One needs to be wary of arguments regarding 
biologic rationale. Almost any new treatment in 
a phase 3 trial has a plethora of supportive sci-
entific data from animal studies and early-phase 
trials. Nonetheless, history is filled with records 
of many large pivotal trials that failed to exhibit 
any signs of efficacy (or that revealed heretofore 
unanticipated safety issues). For instance, the 
hypothesis that raising high-density lipoprotein 
cholesterol levels could be a new means of re-
ducing cardiovascular events looked promising, 
but no trial of inhibitors of cholesteryl ester 
transfer protein has fulfilled that promise.36 Na-
ture often overcomes our best efforts to interrupt 
the order of things. Thus, if methodologic flaws 
in a trial are not the cause of treatment failure, 
it is usually time to “move on,” while trying to 
understand the biologic reasons for the failure.
Discussion
The 12 points explained above can be used to 
provide assistance in deciding what to do next 
when a trial fails to produce a positive finding 
for its primary outcome. Certainly one needs to 
be circumspect. Researchers may opt to move in 
one of three directions.
Declare That the Trial Is Positive
Remarkable circumstances are usually required 
to report that a trial is positive even though the 
results of the primary outcome were not statisti-
cally significant at the prespecified level. The 
descriptions of the findings for the five trials 
listed in Table 2 provide a framework for debate 
as to whether each contained positive findings 
of clinical importance despite the negative pri-
mary outcome. However, although such consider-
ations may inform guidelines committees, regula-
tors are rarely swayed by such secondary analyses.
One notable exception was the CAPRICORN 
trial, which assessed the effects of carvedilol 
versus placebo after myocardial infarction in 
patients with left ventricular dysfunction.37 The 
composite primary outcome — death or hospi-
talization from any cause –– failed to reach 
significance (hazard ratio, 0.92; 95% CI, 0.80 to 
1.07; P = 0.30). But all-cause mortality alone did 
provide some evidence of benefit (hazard ratio, 
0.77; 95% CI, 0.60 to 0.98; P = 0.03) and, after 
much debate, led to FDA approval, perhaps be-
cause all-cause mortality had been the original 
primary outcome (an unfortunate switch was 
made by the investigators midtrial), and external 
evidence existed as to the effectiveness of beta-
blockers in this population of patients.
Improve the Design of Future Trials
Trialists and sponsors usually have strong mech-
anistic support and background evidence that 
justifies the conduct of a major randomized trial. 
Hence, after a disappointing result, explanations 
are sought to guide the effort of designing a 
potential new trial. Aspects to consider include 
adjusting the treatment regimen, altering the 
study population, modifying the primary out-
ASCOT25 and CAPRICORN37: Data from secondary outcomes provided strong 
evidence of superiority
TOPCAT18,19: Findings were positive after the exclusion of outlier countries
SYNTAX23: Data from a study subgroup provided justification for another trial
STICH30,31: Data from the as-treated and per-protocol analyses and from ex-
tended follow-up provided support for the primary outcome
CHARM-Preserved33: Data supporting the study drug were strong after recur-
rent events were incorporated into the analysis
Table 2. Examples of Trials with Positive Claims Despite the Failure of the Primary 
Outcome.
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come, increasing the sample size, and improving 
other aspects of the trial that affected its quality. 
Such difficult and costly decisions should be 
based on realistic expectations rather than naive 
optimism.
For example, after numerous open-label stud-
ies were conducted with highly positive results, 
renal denervation failed to substantially reduce 
blood pressure in patients with refractory hyper-
tension in the sham-controlled SYMPLICITY 
HTN-3 trial.38 Proposed explanations for this 
finding (which few expected) include an unfavor-
able mix of patients (some of whom had hyper-
tension with an underlying cause that made a 
response to renal denervation unlikely), inade-
quate delivery of radiofrequency energy, changes 
in the drug treatment, and the failure to control 
for regression to the mean. Blinded mechanistic 
trials are ongoing in patients with hypertension 
who are not taking any antihypertensive medica-
tion to determine whether renal denervation does 
indeed “work,” before additional, large-scale 
trials are conducted.
Abandon the Treatment as Ineffective
The purpose of randomized trials is to distin-
guish between treatments that are effective and 
those that are not. Unfortunately, many innova-
tions land in the second category. Hence, if the 
overall results of a trial show little or no evi-
dence of treatment efficacy, and especially if there 
are safety issues, it may be wise to desist from 
further investigation. Such a conclusion may fi-
nally have been reached for thrombus aspiration 
in patients with acute myocardial infarction. After 
many years of mixed results from smaller trials, 
two large randomized trials39,40 have now con-
vincingly shown that routine thrombus aspira-
tion has no benefit.
Conclusions
When the primary outcome of a trial fails to 
achieve statistical significance, we propose that 
researchers ask a series of searching questions 
that will help them clarify whether the new treat-
ment may still have value. The options are to 
claim “success” anyway on the basis of the total 
evidence (an option that is rarely used), to plan a 
future trial with design improvements (a costly 
option), or to accept that the new treatment is 
likely to be ineffective (a frustrating option). 
However, the best option is to avoid this sce-
nario altogether through rigorous upfront plan-
ning. By making sure that there is evidence of 
strong pathophysiological and mechanistic under-
pinnings that are common to both the new 
therapy and the disease, by selecting appropriate 
patients and end points, by calculating an ade-
quate sample size, by paying meticulous atten-
tion to dosing, definitions of disease and out-
comes, and all procedural processes, and by 
anticipating the ways in which the trial might 
fail and give rise to criticisms, one can enhance 
the likelihood of reaching a decisive conclusion.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Tim Collier for his help in producing earlier ver-
sions of the figures.
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